CYCLOSERINE

First approved in 1956

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C3H6N2O2
Molecular Weight	102.0919
Optical Activity	( + )
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

N[C@@H]1CONC1=O

InChI

InChIKey=DYDCUQKUCUHJBH-UWTATZPHSA-N

InChI=1S/C3H6N2O2/c4-2-1-7-5-3(2)6/h2H,1,4H2,(H,5,6)/t2-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C3H6N2O2
Molecular Weight	102.0919
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e1e08327-4b90-463e-bb2a-22438cabcef2
Curator's Comment: description was created based on several sources, including ISBN-13: 978-0199337149

Cycloserine was discovered simultaneously in 1954 by Eli Lilly and Merck. The drug was approved for the treatment of active pulmonary and extrapulmonary tuberculosis and marketed under the name Seromycin (among the others). Cycloserine suppresses the synthesis of bacterial wall by inhibitin two enzymes: alanine racemase and d-alanine ligase.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Alanine racemase 2 Target ID: CHEMBL2031 Sources: https://www.ncbi.nlm.nih.gov/pubmed/4919992	Inhibitor 8297
D-alanylalanine synthetase 1 Target ID: CHEMBL2030 Sources: https://www.ncbi.nlm.nih.gov/pubmed/4919992	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Tuberculosis 83 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e1e08327-4b90-463e-bb2a-22438cabcef2	Curative		Approved 8429	SEROMYCIN Approved Use Seromycin is indicated in the treatment of active pulmonary and extrapulmonary tuberculosis (including renal disease) when the causative organisms are susceptible to this drug and when treatment with the primary medications (streptomycin, isoniazid, rifampin, and ethambutol) has proved inadequate. Launch Date 1964

C_max

Value	Dose	Co-administered	Analyte	Population
42.92 mg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/25869627	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:		D-CYCLOSERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
643.29 mg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/25869627	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:		D-CYCLOSERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
13.27 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/25869627	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:		D-CYCLOSERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
1000 mg single, oral Recommended Dose: 1000 mg Route: oral Route: single Dose: 1000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25869627 Page: p.7	healthy, 4.2 n = 12 Health Status: healthy Age Group: 4.2 Sex: M+F Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/25869627 Page: p.7	Sources: https://pubmed.ncbi.nlm.nih.gov/25869627 Page: p.7
250 mg 2 times / day multiple, oral Recommended Dose: 250 mg, 2 times / day Route: oral Route: multiple Dose: 250 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25869627 Page: p.7	healthy, 4.2 n = 12 Health Status: healthy Age Group: 4.2 Sex: M+F Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/25869627 Page: p.7	Sources: https://pubmed.ncbi.nlm.nih.gov/25869627 Page: p.7
50 mg 1 times / week multiple, oral Dose: 50 mg, 1 times / week Route: oral Route: multiple Dose: 50 mg, 1 times / week Sources: https://clinicaltrials.gov/ct2/show/NCT01399866	unhealthy n = 30 Health Status: unhealthy Condition: Nicotine dependence Population Size: 30 Sources: https://clinicaltrials.gov/ct2/show/NCT01399866	Other AEs: Anorexia, Dizziness... Other AEs: Anorexia (below serious, 4 patients) Dizziness (below serious, 4 patients) Restlessness (below serious, 7 patients) Sore throat (below serious, 6 patients) Urticaria (below serious, 5 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT01399866
50 mg single, oral Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: https://clinicaltrials.gov/ct2/show/NCT01086475	unhealthy n = 34 Health Status: unhealthy Condition: Autism Spectrum Disorders Population Size: 34 Sources: https://clinicaltrials.gov/ct2/show/NCT01086475	Other AEs: Headache, Vomiting... Other AEs: Headache (below serious, 9 patients) Vomiting (below serious, 6 patients) Irritability (below serious, 16 patients) Feeling sad (below serious, 5 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT01086475

AEs

AE	Significance	Dose	Population
Anorexia	below serious, 4 patients	50 mg 1 times / week multiple, oral Dose: 50 mg, 1 times / week Route: oral Route: multiple Dose: 50 mg, 1 times / week Sources: https://clinicaltrials.gov/ct2/show/NCT01399866	unhealthy n = 30 Health Status: unhealthy Condition: Nicotine dependence Population Size: 30 Sources: https://clinicaltrials.gov/ct2/show/NCT01399866
Dizziness	below serious, 4 patients	50 mg 1 times / week multiple, oral Dose: 50 mg, 1 times / week Route: oral Route: multiple Dose: 50 mg, 1 times / week Sources: https://clinicaltrials.gov/ct2/show/NCT01399866	unhealthy n = 30 Health Status: unhealthy Condition: Nicotine dependence Population Size: 30 Sources: https://clinicaltrials.gov/ct2/show/NCT01399866
Urticaria	below serious, 5 patients	50 mg 1 times / week multiple, oral Dose: 50 mg, 1 times / week Route: oral Route: multiple Dose: 50 mg, 1 times / week Sources: https://clinicaltrials.gov/ct2/show/NCT01399866	unhealthy n = 30 Health Status: unhealthy Condition: Nicotine dependence Population Size: 30 Sources: https://clinicaltrials.gov/ct2/show/NCT01399866
Sore throat	below serious, 6 patients	50 mg 1 times / week multiple, oral Dose: 50 mg, 1 times / week Route: oral Route: multiple Dose: 50 mg, 1 times / week Sources: https://clinicaltrials.gov/ct2/show/NCT01399866	unhealthy n = 30 Health Status: unhealthy Condition: Nicotine dependence Population Size: 30 Sources: https://clinicaltrials.gov/ct2/show/NCT01399866
Restlessness	below serious, 7 patients	50 mg 1 times / week multiple, oral Dose: 50 mg, 1 times / week Route: oral Route: multiple Dose: 50 mg, 1 times / week Sources: https://clinicaltrials.gov/ct2/show/NCT01399866	unhealthy n = 30 Health Status: unhealthy Condition: Nicotine dependence Population Size: 30 Sources: https://clinicaltrials.gov/ct2/show/NCT01399866
Irritability	below serious, 16 patients	50 mg single, oral Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: https://clinicaltrials.gov/ct2/show/NCT01086475	unhealthy n = 34 Health Status: unhealthy Condition: Autism Spectrum Disorders Population Size: 34 Sources: https://clinicaltrials.gov/ct2/show/NCT01086475
Feeling sad	below serious, 5 patients	50 mg single, oral Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: https://clinicaltrials.gov/ct2/show/NCT01086475	unhealthy n = 34 Health Status: unhealthy Condition: Autism Spectrum Disorders Population Size: 34 Sources: https://clinicaltrials.gov/ct2/show/NCT01086475
Vomiting	below serious, 6 patients	50 mg single, oral Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: https://clinicaltrials.gov/ct2/show/NCT01086475	unhealthy n = 34 Health Status: unhealthy Condition: Autism Spectrum Disorders Population Size: 34 Sources: https://clinicaltrials.gov/ct2/show/NCT01086475
Headache	below serious, 9 patients	50 mg single, oral Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: https://clinicaltrials.gov/ct2/show/NCT01086475	unhealthy n = 34 Health Status: unhealthy Condition: Autism Spectrum Disorders Population Size: 34 Sources: https://clinicaltrials.gov/ct2/show/NCT01086475

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B3-002615	http://www.3bsc.com/index/pro_info.php?id=24506
AA Blocks	AA00IBP7	http://www.aablocks.com/goods/Goods/detail?id=AA00IBP7
AEchem Scientific Corp., USA	AE1-018090	http://www.aechemsc.com/info_products/AE1-018090.php
AK Scientific, Inc. (AKSCI)	K138	http://www.aksci.com/item_detail.php?cat=K138
Aaron Chemicals	AR00ICGZ	http://www.aaronchem.com/68-41-7
AbMole Bioscience	M5554	http://www.abmole.com/products/d-cycloserine.html
Acadechem	ACDS-064964	http://www.acadechemical.com/product/139663
Achemtek	0104-016419	http://www.achemtek.com/68-41-7
Acorn PharmaTech	ACN-034126	http://www.acornpharmatech.com/
Acros Organics	AC228480250	https://www.fishersci.com/shop/products/d-cycloserine-98-acros-organics-2/AC228480250
Acros Organics	AC228480010	https://www.fishersci.com/shop/products/d-cycloserine-98-acros-organics/AC228480010
Acros Organics	AC228480050	https://www.fishersci.com/shop/products/d-cycloserine-98-acros-organics/AC228480050
Adooq BioScience	A10291	https://www.adooq.com/d-cycloserine.html
Alfa Aesar	A18000	https://www.alfa.com/en/catalog/A18000/
Alfa Chemistry	AP68417-A	https://reagents.alfa-chemistry.com/product/cycloserine-cas-68-41-7-15087.html
Alfa Chemistry	AP68417	https://reagents.alfa-chemistry.com/product/d-cycloserine-cas-68-41-7-15086.html
Alfa Chemistry	68-41-7	https://www.alfa-chemistry.com/d-cycloserine-cas-68-41-7-item-293275.htm
Alichem	471000121	http://www.alichem.com/en/products/68-41-7.html
Angene	AGN-PC-0O93A3	http://www.angenechemical.com/productshow/AGN-PC-0O93A3.html
ApexBio Technology	B1721	http://www.apexbt.com/d-cycloserine-28841.html
AstaTech, Inc.	50854	http://www.astatechinc.com/CPSResult.php?CRNO=2085
Aurora Fine Chemicals LLC	K04.000.876	http://online.aurorafinechemicals.com/info?ID=K04.000.876
Aurum Pharmatech LLC	M-3650	http://www.Aurumpharmatech.com/Product/ProductDetails/M_3650
AvaChem Scientific	6241	https://www.avachem.com/productSearch.asp?6241
BLD Pharm	BD9333	http://www.bldpharm.com/products/68-41-7.html
BioSynth	C-9400	http://www.biosynth.com/index.asp?topic_id=97&g=19&m=249&feld=katno&wert=C-9400
BioSynth	C-9390	https://www.biosynth.com/en/products/life-science/culture-media-additives/products/C-9390.html
CSNpharm	CSN19477	https://www.csnpharm.com/products/d-cycloserine.html
Capot Chemical	5763	http://www.capotchem.com/en/5763.htm
Capot Chemical	PubChem5763	http://www.capotchem.com/en/5763.htm
Chem Scene	CS-2395	http://www.chemscene.com/68-41-7.html
ChemMol	1030362	http://www.chemmol.com/chemmol/1030362.html
ChemMol	30111597	http://www.chemmol.com/chemmol/30111597.html
ChemMol	44027239	http://www.chemmol.com/chemmol/44027239.html
ChemMol	99122245	http://www.chemmol.com/chemmol/99122245.html
Chemenu	CM110202	http://www.chemenu.com/products/CM110202
Chemspace	CSSB00000765999	https://chem-space.com/CSSB00000765999
DC Chemicals	DCAPI1304	http://www.dcchemicals.com//product_show-D_Cycloserine.html
Enamine	Z1522567171	https://www.enaminestore.com/catalog/Z1522567171
Glentham Life Sciences	GA9717	http://www.glentham.com/products/product/GA9717/
Hello Bio	HB0234	http://www.hellobio.com/dcycloserine.html
LGC Standards	DRE-C11836200	https://www.lgcstandards.com/US/en/p/DRE-C11836200
LGC Standards	LGCFOR3028.00	https://www.lgcstandards.com/US/en/p/LGCFOR3028.00
LGC Standards	MM3028.00	https://www.lgcstandards.com/US/en/p/MM3028.00
Lab Network	LN00173123	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00173123
Matrix Scientific	72929	https://www.matrixscientific.com/072929.html
MedChem Express	HY-B0030	https://www.medchemexpress.com/D-Cycloserine.html
OChem	2077	http://www.ocheminc.com/index.php?act=psearch&pid=005C353
Parchem	117245	https://www.parchem.com/chemical-supplier-distributor/4-Aminoisoxazolidin-3-one-117245.aspx
Renno Tech	RL04615	http://www.rennotech.com/product_show.asp?id=4864
Shanghai Send Pharmaceutical Technology Co., Ltd	send32482	http://shsendpharm.com/
Sigma-Aldrich	PHR1765_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/phr1765?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	30020_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/30020?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	C3909_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/c3909?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	C6880_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/c6880?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	1158005_USP	https://www.sigmaaldrich.com/catalog/product/usp/1158005?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S049307	http://www.sinfoobiotech.com/product/1052705
Smolecule	S524744	http://www.smolecule.com/products/s524744
Smolecule	S793365	https://www.smolecule.com/products/s793365
TCI (Tokyo Chemical Industry)	C1189	http://www.tcichemicals.com/eshop/en/us/commodity/C1189/index.html
THE BioTek	bt-266218	https://www.thebiotek.com/product/inhibitors/bt-266218
VladaChem	VL141602	https://www.vladachem.com/product.php?products=68-41-7
VladaChem	VL263773-1G	https://www.vladachem.com/product.php?products=68-41-7
Watanabe Chemical Ind.	H00231	https://www.watanabechem.co.jp/en/search/details.php?code=H00231
Yuhao Chemical	LT4743	http://www.chemyuhao.com/68-41-7.html
abcr GmbH	AB115191	http://www.abcr.com/shop/en/AB115191
abcr GmbH	AB402793	http://www.abcr.com/shop/en/AB402793
eNovation Chemicals	D492514	https://www.enovationchem.com/ProductDetails.asp?ProductID=D492514
eNovation Chemicals	D682049	https://www.enovationchem.com/ProductDetails.asp?ProductID=D682049
eNovation Chemicals	D910419	https://www.enovationchem.com/ProductDetails.asp?ProductID=D910419
eNovation Chemicals	Y1050283	https://www.enovationchem.com/ProductDetails.asp?ProductID=Y1050283
iChemical	EBD2198208	http://www.ichemical.com/products/68-41-7.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
mcule	MCULE-4212827696	https://mcule.com/MCULE-4212827696/

PubMed

Title	Date	PubMed
Cycloserine: antituberculous activity in vitro and in the experimental animal.	1956 Apr	13302684
Spectrum of drugs against atypical mycobacteria: how valid is the current practice of drug susceptibility testing and the choice of drugs?	1992 Dec	1303690
Role of specific aminotransferases in de novo glutamate synthesis and redox shuttling in the retina.	2001 Dec 1	11746419
Involvement of cholinergic and glutamatergic functions in working memory impairment induced by interleukin-1beta in rats.	2001 Nov 2	11711044
Effects of N-methyl-D-aspartate agonists and antagonists in rats discriminating amphetamine.	2001 Sep	11710746
RS 67333 and D-cycloserine accelerate learning acquisition in the rat.	2001 Sep	11543772
Determination of cycloserine in human plasma by high-performance liquid chromatography with fluorescence detection, using derivatization with p-benzoquinone.	2001 Sep 15	11585129
[Effect of glutoxim in the combination with antitubercular agents of the second choice on the growth of drug resistant Mycobacteria tuberculosis in the cultured murine lung tissue].	2002	12422643
Direct calcium binding results in activation of brain serine racemase.	2002 Aug 2	12021263
Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder.	2002 Dec	12466030
Homer 1a gene expression modulation by antipsychotic drugs: involvement of the glutamate metabotropic system and effects of D-cycloserine.	2002 Dec	12464447
Ceramide signaling in fenretinide-induced endothelial cell apoptosis.	2002 Dec 20	12388538
A case series of D-cycloserine added to donepezil in the treatment of Alzheimer's disease.	2002 Fall	12426422
D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia.	2002 Jul 1	12084415
A pathway-specific cell based screening system to detect bacterial cell wall inhibitors.	2002 Mar	12014443
Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia.	2002 Mar	11870017
Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats.	2002 Mar 15	11896173
[Pharmacological support of exposure therapy in anxiety disorders. Animal experiment studies].	2002 May	12078031
Molecular epidemiology of multidrug-resistant tuberculosis, New York City, 1995-1997.	2002 Nov	12453347
Molecular epidemiology of tuberculosis in a sentinel surveillance population.	2002 Nov	12453343
Structural studies of Salmonella typhimurium ArnB (PmrH) aminotransferase: a 4-amino-4-deoxy-L-arabinose lipopolysaccharide-modifying enzyme.	2002 Nov	12429098
Effects of D-cycloserine on extinction of conditioned freezing.	2003 Apr	12708530
Subunit interaction of monomeric alanine racemases from four Shigella species in catalytic reaction.	2003 Apr 25	12725937
Multidrug-resistant tuberculosis in HIV-negative patients, Buenos Aires, Argentina.	2003 Aug	12967495
D-cycloserine-Naloxone interactions in opioid-dependent humans under a novel-response naloxone discrimination procedure.	2003 Aug	12940503
Substrate reduction intervention by L-cycloserine in twitcher mice (globoid cell leukodystrophy) on a B6;CAST/Ei background.	2003 Aug 14	12865135
In vitro activity of C-8-methoxy fluoroquinolones against mycobacteria when combined with anti-tuberculosis agents.	2003 Dec	14613961
N(2)-substituted D,L-cycloserine derivatives: synthesis and evaluation as alanine racemase inhibitors.	2003 Feb	12715876
Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice.	2003 Jan	12499213
Effects of antibiotics that inhibit the bacterial peptidoglycan synthesis pathway on moss chloroplast division.	2003 Jul	12881507
D-cycloserine for the treatment of ataxia in spinocerebellar degeneration.	2003 Jun 15	12736088
A side reaction of alanine racemase: transamination of cycloserine.	2003 May 20	12741835
D-cycloserine facilitates synaptic plasticity but impairs glutamatergic neurotransmission in rat hippocampal slices.	2003 Nov	14530208
Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong.	2003 Oct	14555582
Genome-wide transcriptional profiling of the response of Staphylococcus aureus to cell-wall-active antibiotics reveals a cell-wall-stress stimulon.	2003 Oct	14523105
Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid.	2004	15525560
Pharmacy data for tuberculosis surveillance and assessment of patient management.	2004 Aug	15496244
New agents active against Mycobacterium avium complex selected by molecular topology: a virtual screening method.	2004 Jan	14645324
Responsiveness to brightness change in male and female rats following treatment with the partial agonist of the N-methyl-D-aspartate receptor, D-cycloserine.	2004 Jul 9	15196787
Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus.	2004 Jun	15182147
Psychiatric issues in the management of patients with multidrug-resistant tuberculosis.	2004 Jun	15182146
D-cycloserine and the facilitation of extinction of conditioned fear: consequences for reinstatement.	2004 Jun	15174928
Surprises and omissions in toxicology.	2004 Mar	15141993
Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea.	2004 Mar	15139476
Model structures of the N-methyl-D-aspartate receptor subunit NR1 explain the molecular recognition of agonist and antagonist ligands.	2004 Mar	14960371
Ceramide synthesis correlates with the posttranscriptional regulation of the sterol-regulatory element-binding protein.	2004 May	15132973
Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear.	2004 Nov	15520361
A pilot study of D-cycloserine in subjects with autistic disorder.	2004 Nov	15514414
Multidrug resistant miliary tuberculosis and Pott's disease in an immunocompetent patient.	2004 Oct	15494824
Cell-surface alterations in class IIa bacteriocin-resistant Listeria monocytogenes strains.	2004 Sep	15347760

Patents

Sample Use Guides

In Vivo Use Guide

The usual dosage is 500 mg to 1 g daily in divided doses monitored by blood levels. The initial adult dosage most frequently given is 250 mg twice daily at 12–hour intervals for the first 2 weeks. A daily dosage of 1 g should not be exceeded.

Route of Administration: Oral

In Vitro Use Guide

Multidrug resistant Mycobacterium tuberculosis isolates were incubated with 20 uL of cycloserine. 5 different cycloserine concentrations (8, 16, 32, 64, and > 64 ug/mL).

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:12:34 GMT 2023` Edited by `admin` on `Fri Dec 15 15:12:34 GMT 2023`
Record UNII	95IK5KI84Z
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CYCLOSERINE

Official Name

English

(+)-4-AMINO-3-ISOXAZOLIDINONE

Systematic Name

English

CYCLOSERINE [WHO-IP]

Common Name

English

SEROMYCIN

Brand Name

English

CYCLOSERINE [USP MONOGRAPH]

Common Name

English

CYCLOSERINE [MI]

Common Name

English

CYCLOSERINUM [WHO-IP LATIN]

Common Name

English

D-CYCLOSERINE

Common Name

English

ORIENTOMYCIN

Common Name

English

3-ISOXAZOLIDINONE, 4-AMINO-, (R)-

Systematic Name

English

CYCLOSERINE [USP IMPURITY]

Common Name

English

NSC-76029

Code

English

CYCLOSERINE [ORANGE BOOK]

Common Name

English

cycloserine [INN]

Common Name

English

CYCLOSERINE [VANDF]

Common Name

English

Cycloserine [WHO-DD]

Common Name

English

NSC-154851

Code

English

CYCLOSERINE [JAN]

Common Name

English

CYCLOSERINE [HSDB]

Common Name

English

CYCLOSERINE [MART.]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QJ04AB01